p56^lckexpression in type 1 diabetes

Type 1 diabetes is a T cell-mediated autoimmune disease leading to the destruction of pancreatic islet ? cells. This disease is associated with numerous immunological abnormalities. A characteristic abnormality is decreased proliferation and altered cytokine production by T lymphocytes when exposed to TCR/CD3 agonists in vitro. This phenotype can be reversed by addition of costimulatory signals (eg combination of CD2/CD28 antibodies or exogenous cytokines), suggesting a constitutive defect in the TCR/CD3 signal transduction pathway. In T lymphocytes, TCR/CD3 engagement induces CD3?-chain phosphorylation by p56^lck or p59^fyn tyrosine kinases. CD3?-chain phosphorylation allows the docking and the phosphorylation of ZAP-70 tyrosine kinase, which in turn phosphorylates neighboring proteins such as linker for activation of T cells (LAT). After recruitment of various adaptor proteins, key effector enzymes such as phospholipase C ? (PLC-?) are activated. The authors studied TCR/CD3 transduction pathway in isolated T lymphocytes.

The CD3?-chain was hypophosphorylated in 70% of the patients tested versus none of control subjects. By contrast, phosphorylation of ZAP-70 was unaffected. The patients with CD3?-chain hypophosphorylation had reduced expression of p56^lck in resting lymphocytes. The authors did not observe a decrease of p59^fyn, LAT, PLC-? or PI3kinase expression. In some patients, this defect was linked to low level of p56^lckmRNA, and resulted in the failure to efficiently induce the expression of the CD69 early activation marker. The authors propose that T cell deficiency in human type 1 diabetes is due to the selective decreased expression of the p56^lck tyrosine kinase.

The functional consequences of the p56^lck defect are of interest because (1) during intrathymic maturation, the preferential association of p56^lck with TCR/CD3 is required for the appropriate adjustment of threshold responses to autoantigens; and (2) differentiation toward the Th2 lineage requires high levels of recruited p56^lck kinase, and diabetes in a non-obese diabetic mouse model is associated with a relative reduction of the Th2/Th1 cell ratio. More experiments are required to prove the role of this defect in diabetes development. However, the description of a constitutive T cell signalling abnormality in a T cell mediated autoimmune disease will permit further insights into how tolerance is broken down in diabetes and other autoimmune diseases.

T cell activation, western blot, immunoprecipitation,